Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients

Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity remain uncertain; consequently, we sought to compare Sac/Val vs. standard medical therapy, in terms of effects on...

Full description

Bibliographic Details
Main Authors: Alfonso Campanile, Valeria Visco, Stefania De Carlo, Germano Junior Ferruzzi, Costantino Mancusi, Carmine Izzo, Felice Mongiello, Paola Di Pietro, Nicola Virtuoso, Amelia Ravera, Domenico Bonadies, Carmine Vecchione, Michele Ciccarelli
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Life
Subjects:
sacubitril/valsartan
heart failure
HFrEF
CPET
exercise capacity
peak VO<sub>2</sub>
Online Access:https://www.mdpi.com/2075-1729/13/5/1174

Internet

https://www.mdpi.com/2075-1729/13/5/1174

Similar Items